- Home
- MIST vs CRDF Comparison
MIST vs CRDF Comparison
Compare MIST & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | CRDF |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3M | 82.5M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MIST | CRDF |
|---|---|---|
| Price | $0.70 | $0.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $5.86 | $5.81 |
| AVG Volume (30 Days) | ★ 1.1M | 442.1K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | $147.62 | N/A |
| Revenue Next Year | $476.43 | $8.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $0.70 | $0.76 |
| 52 Week High | $3.06 | $3.31 |
Technical Indicators
Market Signals| Indicator | MIST | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 34.67 | 30.24 |
| Support Level | N/A | $0.88 |
| Resistance Level | $1.42 | $1.13 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 8.54 | 4.34 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.